INTRODUCTION
Psoriasis is a difficult condition to treat, and it is often accompanied by comorbidities that confound diagnosis and complicate management.
The literature on such scenarios is sparse, as patients with unusual or complex disease and comorbidities are typically excluded from clinical trials.
A consensus panel of 14 experts in the field of psoriasis was formed to conduct a Delphi method exercise to identify challenging clinical scenarios and to rank treatment approaches, in an effort to provide guidance to the practicing clinician.
Part 1 in this series presented six scenarios from this Delphi exercise: (1) psoriasis and human papilloma virus (HPV)-induced cervical or anogenital dysplasia; (2) concomitant psoriasis and systemic lupus erythematosus; (3) severe psoriatic nail disease causing functional or emotional impairment; (4) psoriasis therapies that potentially reduce cardiovascular morbidity and mortality; (5) older patients (C65 years of age) with psoriasis; and (6) severe scalp psoriasis that is unresponsive to topical therapy [1] . The current paper presents five additional scenarios of interest to the practicing dermatologist: (1) moderate-to-severe psoriasis that has failed to respond to all currently characteristics: (1) repeated individual questioning of the experts; (2) the avoidance of direct confrontation among the experts (e.g., anonymity); and (3) interspersed controlled opinion and feedback. Importantly, the Delphi method seeks to achieve consensus on complex scenarios where rigorous data are lacking.
Available data on a given topic are reviewed extensively, presented, and discussed amongst the panelists. More importantly, by employing only anonymous voting by the panelists, anonymous; thus, at no point was a single individual able to direct the outcome of any aspect of this process.
Method Overview
The employed Delphi exercise process is described in full in Part 1 of this study [1] . In brief, it began with the identification of 14 psoriasis experts from the United States (US). Individually, the panelists were asked to list challenging clinical scenarios and therapeutic options for psoriasis. The clinical scenarios were then selected and ranked, and the treatment options were listed. Twenty-four of the top-ranked scenarios were discussed during a live meeting and the treatment choices for each were voted on and ranked.
Classification of Experimental Evidence
Supporting a Therapeutic Option possibly, malignant melanoma (grade C evidence) [5] .
Combinations of phototherapy with other agents have been reported, allowing it to be an adjuvant to any of the prior failed monotherapy options. Acitretin and UVB therapy have greater efficacy than UVB therapy alone (grade A evidence) [6] . The acitretin and PUVA combination also has a higher clearance rate than PUVA alone and has the additional benefit of reducing the total PUVA exposure by 42% (grade A evidence) [7] . One study focused on the treatment of patients who were refractory to monotherapy with either narrowband or broadband UVB therapy, monotherapy with acitretin, or the combination of acitretin with broadband UVB. The most successful approach in these patients was a combination of acitretin with narrowband UVB, which resulted in 72.5% of patients reaching a PASI 75 (grade C evidence) [8] .
UV light has been combined with a few biologics, notably etanercept and alefacept. In a study of etanercept and narrowband UVB therapy, 85% of patients reached a PASI 75 after 12 weeks (grade C evidence) [9] . However, there were no monotherapy data for comparison, and general expectations would be a 73% clearance rate from UVB therapy alone [3] . Using a split-body study, alefacept was able to reduce PASI scores by 62%, and the addition of narrowband UVB therapy reduced the scores by 81% (grade A evidence) [10] . However, when the combination was compared to narrowband UVB therapy alone in a separate study, no significant difference was detected in patient response (grade A evidence) [11] . Some other therapeutic options include abatacept and 6-thioguanine, which are more commonly utilized in rheumatoid arthritis (RA).
An initial trial of abatacept for psoriasis revealed a dose-dependent response and resulted in 46% of patients achieving a PASI 50 (grade A evidence) [12] . This improvement was seen in a population previously resistant to methotrexate, cyclosporine, phototherapy, or systemic corticosteroids. In addition, clinical improvement correlated with histological changes and reductions in T-cell activation (grade C evidence) [13] . While abatacept presents a new option for recalcitrant psoriasis, there currently is a lack of placebo-controlled studies and the optimal dose and dosing interval are unknown. In the RA population, there is an increased risk of serious infections and a higher rate of adverse events in patients with chronic obstructive pulmonary disease (COPD), and a requirement for ongoing monitoring for the risk of lung carcinoma and lymphoma (grade D evidence) [14] . For 6-thioguanine, there has been a high success rate, with 78% of patients clearing the majority, or all, of their lesions (grade C evidence) [15, 16] . Over 50% of the patients were able to maintain their results for 2 years. Despite the drug's efficacy, 35 .5% of patients discontinued the therapy due to intolerable side effects. The most frequent toxicity from daily dosing is myelosuppression, found in up to 46.9% of patients. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels also may increase, although these elevations do not correlate with chronic liver disease. Pulse dosing has similar efficacy to daily dosing, but may lower the risk of adverse events (grade B evidence) [17] .
In small clinical trials, mycophenolate mofetil reduced mean severity scores by 56% as compared with 9% for placebo (grade A evidence) [18, 19] . Over the course of treatment, significant improvement was noticeable by 6 weeks and 61% of treated patients reached a PASI 50 by week 12 (grade B evidence) [20] . Mycophenolate mofetil was also well tolerated with mild gastrointestinal effects, but the risk of leucopenia and the complications of immunosuppression remain (grade C evidence) [21] .
Topical therapies may also have a role in recalcitrant psoriasis. A once-daily application of calcipotriene combined with corticosteroids was found to induce a 72% reduction in PASI scores by week 4, which is a higher efficacy than seen with biologic agents (grade C evidence) [22] .
However, with severe disease encompassing a large body surface area, there may arise significantly increased cost, poor patient adherence, potential hypothalamuspituitary axis suppression, and the cutaneous side effects of topical corticosteroids (grade B evidence) [23] . Treatment Challenges: None.
Case Scenario 2. PPP that is Unresponsive to Topical Therapy and Phototherapy
While there are few data on the overall prevalence of PPP, approximately 17% of patients with psoriasis have palmar or plantar involvement (grade C evidence) [24] . Conversely, in those with PPP, a range of 2-24% will have evidence of psoriasis elsewhere [25] . However, the demographics differ in PPP from typical psoriasis, with a much higher incidence in women and a strong association to smoking (grade C evidence) [26] . Patients with palmoplantar involvement also experience higher rates of physical discomfort and disability (grade C evidence) [27] . Low-dose cyclosporine, short-course tetracycline, and Grenz ray (low voltage X-ray therapy) were Fig. 1 Final results of the voting on case scenario 1, moderate-to-severe psoriasis that has failed to respond to all currently approved therapies for psoriasis. a denotes P\0.05 compared with ustekinumab therapy; b denotes P\0.01 compared with UVB-NB therapy; c denotes P\0.05 compared with UV ? acitretin therapy; d denotes P\0.01 compared with UVB-BB therapy; e denotes P\0.05 compared with UV-PUVA therapy. PUVA psoralen ? ultraviolet A therapy, UV ultraviolet therapy, UVB-BB broadband ultraviolet B therapy, UVB-NB narrowband ultraviolet B therapy found to improve PPP, but were unable to clear the disease. For topical therapies, the use of topical steroids under hydrocolloid occlusion was beneficial in inducing remission [28] .
Several case reports suggest that the TNF-a inhibitors may be a viable therapeutic choice for PPP (grade D evidence) [29] [30] [31] [32] . The various TNF-a inhibitors may be used in sequence with each other or in combination with acitretin (grade D evidence) [32, 33] . However, all three TNF-a agents, when used for the treatment of Treatment Challenges: None.
Case Scenario 3. Erythrodermic Psoriasis
Hebra initially described erythroderma in 1868
as an exfoliative dermatitis involving more than 90% of the body surface, but today's definition remains nebulous as there are numerous etiologies for erythroderma. While the differential diagnosis may include systemic diseases, such as leukemia and lymphoma, a systemic drug reaction, or a paraneoplastic presentation of underlying cancer, the majority of cases arise from pre-existing skin Fig. 2 Final results of the voting on case scenario 2, palmoplantar psoriasis that is unresponsive to topical therapy and phototherapy. a denotes P\0.01 compared with cyclosporine therapy. MTX methotrexate, pref preferred, TNFI tumor necrosis factor inhibitor disease (grade C evidence) [35, 36] . Psoriasis may represent up to 40% of those cases [37] . Those with erythroderma also face a higher mortality rate than age-matched controls, and patients with psoriasis may be specifically at risk for staphylococcal septicemia (grade D evidence) [37] .
Currently, there is a paucity of data to guide treatment, as erythrodermic psoriasis is almost always an exclusionary criterion in clinical trials. In a group of 33 patients, however, cyclosporine led to complete disease remission in 67% after 3 months and an overall response rate of 94% (grade B evidence) [38] . There are other also case reports supporting the efficacy of cyclosporine as a monotherapy and in combination with acitretin (grade D evidence) [39] [40] [41] . Monotherapy with both etretinate (grade A evidence) [42] and acitretin (grade C evidence) [43] demonstrated efficacy, although erythroderma was reported as a complication of acitretin use (grade D evidence) [44] .
For the TNF-a inhibitors, there are cases of successful therapy with infliximab alone (grade D evidence) [45] [46] [47] [48] and one case responding to a combination with cyclosporine (grade D evidence) [49] . There are no data for the use of methotrexate as monotherapy, although success with methotrexate in combination with etretinate has been reported (grade D evidence) [50] . Both adalimumab and etanercept have reports of success (grade B evidence) [51, 52] . While etanercept may take up to 24 weeks for substantial improvement, six out of 10 patients achieved a PASI 75 response.
Discussion
During the discussion of this case, panelists highlighted the differences in erythrodermic presentation. While in some cases it may be quite acute, other scenarios display a slow onset with a chronic clinical picture. With its rapid onset of action, cyclosporine was mentioned as the favored therapeutic agent for acute cases. Identification of the cause is fundamental, as resolving the underlying disorder should be the first intervention. For psoriasis-specific therapy, the rapidity of the response, the ability to maintain the response, and the safety of the agent must all be considered. For generalized pustular psoriasis, there are no RCTs and the majority of clinical evidence derives from case reports. Cyclosporine has been efficacious for generalized pustular psoriasis in its juvenile form [53] , in pregnancy [54] , and in adults (grade D evidence) [55, 56] . It has a rapid onset of action. The major toxicity is from dosedependent renal damage, occurring mostly with high-dose or long-term treatment (grade A evidence) [57] . Accordingly, most recommendations are to limit cyclosporine exposure to 1-2 years, and some cases require a transition medicine for further treatment (grade D evidence) [58] .
In the prevention of recurrent pustules, acitretin has been shown to be effective (grade D evidence) [59, 60] . Etretinate has evidence for moderate improvement to complete clearance in generalized pustular psoriasis, but is no longer commercially available (grade A evidence) [42] . Acitretin has shown efficacy in children as young as 2.5 months (grade D evidence) and in adults, with visible results in fewer than 10 days (grade C evidence) [37, 59] .
A recent study from France found that acitretin was the first-line treatment in 89% of cases (grade C evidence) [60] . Combining acitretin with narrowband UVB phototherapy may be synergistic, and has demonstrated efficacy for pustular psoriasis in childhood (grade D evidence) [61, 62] . Narrowband UVB therapy, with or without topical corticosteroids, is of particular use during pregnancy, when many therapeutic options have unknown teratogenic risks (grade D evidence) [63] .
Methotrexate effectively treats pustular psoriasis in children (grade B evidence) [64] and adults (grade C evidence) [65] [66] [67] . The successful combination of methotrexate and cyclosporine for severe pustular psoriasis associated with psoriatic arthritis has also been reported (grade B evidence) [68, 69] . For the arthritis component, the combination may reduce joint inflammation, but does not alter pain levels and overall quality of life (grade A evidence) [70] . Because cyclosporine and methotrexate are associated with potential renal and hepatic damage, respectively, some have discouraged the combination due to concerns of additive toxicity (grade D evidence) [71] , but dose reduction of the two individual drugs when used together may reduce risk.
A study from Japan found that retinoids had the highest success rate at 84.1%, followed by methotrexate (76.2%), cyclosporine (71.2%), PUVA (45.7%), and tonsillectomy for those with recurrent streptococcal pharyngitis (16.7%) (grade C evidence) [67] . Systemic corticosteroids were also found to be efficacious when used only in the presence of severe systemic symptoms.
Of 
Fortunately, generalized pustular psoriasis is a rare entity. Some panelists shared their approach of treating with a medicine that is fast and useful in the short term, followed by a transition to a longer-term medication. Others stated that they preferred to use one agent, such as infliximab, throughout therapy. One panelist pointed out that some patients will have complete resolution of their disease after the initial treatment, while a subset will have recurrences.
In discussing the option of transitioning from one TNF-a inhibitor to another, such as infliximab to etanercept as described above, the group agreed that this approach is not commonly done. Some warned that infliximab has been shown to sometimes have a loss of efficacy with intermittent use, so that if the transition is made, the drug might no longer be an option for further use if needed later.
Overall, the majority of the panel considered cyclosporine as their first-line agent, both for its ease of prescription and rapid onset of action.
Others favored infliximab as the first-line treatment. Acitretin was questioned in this setting, as its onset of action would be slower than other agents that were mentioned, but it remained an option given its recognized efficacy.
The top-ranked treatments for this condition were cyclosporine, infliximab, a TNF-a inhibitor (infliximab preferred), methotrexate ? a TNF-a inhibitor, methotrexate alone, acitretin ? a biologic agent, acitretin alone, methotrexate ? cyclosporine, and UV phototherapy ? acitretin. [97] .
Overall, the panelists emphasized the lack of psoriasis-specific data for agents to combine with methotrexate and noted that most of the evidence and conclusions available are based on extrapolations from the RA data. In addition, while combination therapies may be effective, they each have their own set of individual risk profiles and patient comorbidities that may limit therapeutic options.
The combination of cyclosporine and methotrexate was suggested with great trepidation. Initial data suggested utility in the control of skin and joint disease at lower doses in combination than either would require as a monotherapy. However, renal toxicity, which is not reversible with cyclosporine taper, was detected on long-term combination treatment (grade B evidence) [69] . In a separate study of patients with plaque, pustular, or erythrodermic psoriasis, with or without arthritis, the combination of cyclosporine and methotrexate reduced PASI scores by a median of 77.4%, but also induced a proportion of patients to develop altered renal or liver function (grade B evidence) [68] . Panelist opinion varied on this subject, with some using this combination frequently, others refusing to use the combination after experience with significant adverse events, and others replacing cyclosporine with biologic agents.
The top-ranked treatments for this case scenario were a TNF-a inhibitor (etanercept preferred), a TNF-a inhibitor (adalimumab preferred), a TNF-a inhibitor (infliximab preferred), adalimumab, infliximab, narrowband UV therapy, acitretin, alefacept, and cyclosporine. 
DISCUSSION
This investigation further employs the Delphi process to determine acceptable treatment recommendations in difficult-to-treat psoriasis patients. An additional five case scenarios discussed at the live meeting are presented in this paper: moderate-to-severe psoriasis that has failed to respond to all currently approved therapies for psoriasis in patients who cannot receive methotrexate or cyclosporine; PPP that is unresponsive to topical therapy and phototherapy; erythrodermic psoriasis; pustular psoriasis; and the preferred therapeutic choice to combine with low-dose methotrexate. Six other cases were presented in a separate article [1] .
As described previously, the iterative and anonymous voting process of the Delphi method depends on an unbiased view of the available clinical data and leads to more objective consensus. The final rankings should be viewed as guidance for practical, potentially effective, and likely safe treatment in a majority of instances. Because the Delphi method does not introduce better data for a given topic, it cannot produce an idealized outcome. The process we have utilized selects rational treatment choices for each clinical scenario, but these choices often are not supported by rigorous studies. Importantly, this evidencebased approach relying on anonymous opinion is a more objective tool for reaching consensus.
The process has multiple limitations, all enumerated in Part 1 of this analysis [1] ; however, the Delphi exercise helps clinicians in practice benefit from more objective consensus opinion, offering guidance during challenging clinical scenarios, and allowing for the use of specific treatment approaches that often are effective and safe.
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